Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, vandetanib (Caprelsa®) cannot be endorsed for use within NHS Wales for the treatment of aggressive and symptomatic medullary thyroid cancer in children and adolescents aged 5 years to 18 years with unresectable locally advanced or metastatic disease. |
||
|
||
Medicine details |
||
| Medicine name | vandetanib (Caprelsa®) | |
| Formulation | 100 mg film-coated tablet, 300 mg film-coated tablet | |
| Reference number | 3349 | |
| Indication | For the treatment of aggressive and symptomatic medullary thyroid cancer in children and adolescents aged 5 years to 18 years with unresectable locally advanced or metastatic disease. |
|
| Company | Genzyme Therapeutics | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 07/08/2017 | |
| Date of issue | 08/08/2017 | |